TTD_Target_ID	Target_Name	TTD_Drug_ID	Drug_Name	Drug_Highest_Status	Drug_PubchemID	Molecular_Formula	Molecular_Weight	Canonical_SMILES	Activity	Binder_Type
T64795	Voltage-gated calcium channel alpha Cav3.1	BBOD35	3-(4-Chlorobenzyl)-N-[2-(dimethylamino)ethyl]-4-oxo-2-thioxo-1,2,3,4-tetrahydroquinazoline-7-carboxamide	Investigative	4597377	C20H21ClN4O2S	416.9	CN(C)CCNC(=O)C1=CC2=C(C=C1)C(=O)N(C(=S)N2)CC3=CC=C(C=C3)Cl	IC50 = 53500 nM	Poor binder
T64795	Voltage-gated calcium channel alpha Cav3.1	BFT59I	Methyl 2-(4-bromophenyl)-2-isopropyl-5-(4-(2-methoxyphenyl)piperazin-1-yl)pentanoate	Investigative	44577963	C26H35BrN2O3	503.5	CC(C)C(CCCN1CCN(CC1)C2=CC=CC=C2OC)(C3=CC=C(C=C3)Br)C(=O)OC	IC50 = 95040 nM	Poor binder
T64795	Voltage-gated calcium channel alpha Cav3.1	BOW87G	N-((4-Phenyl-2-propyloxazol-5-yl)methyl)-3-(4-p-tolylpiperazin-1-yl)propan-1-amine	Investigative	49798276	C27H36N4O	432.6	CCCC1=NC(=C(O1)CNCCCN2CCN(CC2)C3=CC=C(C=C3)C)C4=CC=CC=C4	IC50 = 130010 nM	Poor binder